Chris Bakal, Chief Executive Officer at Sentinal4D, shared a post on LinkedIn:
“Most cancer patients don’t respond to immunotherapy. Not because the therapy doesn’t work, but because their tumours are invisible to the immune system.
At The Institute of Cancer Research working with Sentinal4D, Imperial College London and Eidolon Therapeutics, we’re using AI to discover a new class of immunogenic modulators that flip “cold” tumours hot. This makes them visible, triggering the immune system, and opening the door to immunogenic cancer death.
I’ve sketched out how this works below. But the assets are in development, and many more to come.
This is what AI is built to do. Find new therapies.
This is part of what we’re calling the FORGE project. Using AI to discover and characterise new cancer therapies. We’re building it, and we’re looking for partners to build it with.
Project led by Qiyun Zhong, and supported by Rosetrees and Terry Fox Run UK!”
Other articles about Immunotherapy.